PD-L1 is a widely used biomarker for cancer patient selection for checkpoint inhibitors, a class of cancer drugs representing ...

Researchers from Zhejiang Jieyuan Med-Tech Co. Ltd. and collaborators have reported the design and preclinical characterization of a novel series of benzylamine derivatives acting as PD-1/PD-L1 ...

Joshua K. Sabari, MD, discusses the anticipated clinical benefits of adding tarlatamab to durvalumab as maintenance therapy ...

Ultimately, the research showed that immune cells need physical as well as chemical cues to properly manage PD-1 activity, ...

The PD-1 and PD-L1 inhibitor market is expected to reach USD 170.01 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 18.3% from 2024 to 2031. BURLINGAME, CA, UNITED STATES ...

New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has ...

Adding PD-(L)1 inhibitors to chemotherapy improved outcomes, but PD-(L)1 inhibitors alone were no more effective than chemotherapy alone in patients with gastric, gastroesophageal junction, and ...